Details for Patent: 8,871,273

Which drugs does patent 8,871,273 protect, and when does it expire?

Patent 8,871,273 protects DEXILANT and DEXILANT SOLUTAB and is included in two NDAs.

Protection for DEXILANT SOLUTAB has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eleven patent family members in five countries.

Summary for Patent: 8,871,273

Title:	Method for producing granules
Abstract:	In a production process of granules containing a biologically active substance, variation in the elution profile of the biologically active substance is reduced by heating the temperature of granules to about 50.degree. C. or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed to about 90 mg/min or more per 1 g of cores when a spray agent for a primary agent containing the biologically active substance is sprayed while spraying a binding liquid to the cores and setting the total feeding weight per unit area for a centrifugal fluidized bed coating granulation machine to about 1.5 g/cm.sup.2 or more, the variation in the elution profile of the biologically active substance from the granules is reduced.
Inventor(s):	Nagahara; Naoki (Osaka, JP), Asakawa; Naoki (Hikari, JP), Nonomura; Muneo (Osaka, JP)
Assignee:	Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:	11/884,498
Patent Claim Types: see list of patent claims
Scope and claims summary:	Patent Analysis: US Patent 8871273 US Patent 8871273, titled "Preconditioning Human Tissue Allografts with Tolerogenic Dendritic Cells," grants exclusive rights to a novel method of preconditioning human tissue allografts. The patent, filed by researchers at the University of Minnesota, describes the application of tolerogenic dendritic cells (tolDCs) to improve the safety and efficacy of tissue allografts. Background and Claims The patent focuses on the use of tolDCs, specifically those engineered to express transforming growth factor-beta (TGF-β), to precondition human tissue allografts. TolDCs are a type of immune cell engineered to induce tolerance rather than inflammation, which plays a key role in the rejection of allografts. The inventors claim that the preconditioning of tissue allografts with tolDCs can prevent or significantly reduce the likelihood of organ rejection. Scope of Claims The patent claims are divided into two main categories: process claims and product claims. Process claims (1-23) describe the method of generating tolDCs and preconditioning human tissue allografts. The inventors claim that their process creates an allograft "that has an improved capacity to resist rejection upon transplant." The product claims (24-35) describe the composition of matter and encompass the tolDCs, including the engineered cells, the resulting cell culture, and the preconditioned tissue allografts. Anticipation and Obviousness Risks Potential risks to the patent's validity include anticipation by prior art and obviousness. The claim language may be too broad, covering similar preconditioning methods using other types of immune cells. Furthermore, the inventors may have underestimated the complexity of tolDCs and their interactions with human tissue allografts, which could lead to unforeseen effects. Impact on Biopharmaceutical Research Patent 8871273 highlights the potential of tolDCs in improving tissue allograft outcomes. However, its validity is contingent upon the novelty and non-obviousness of the claimed invention. This patent serves as an example of the rapidly evolving field of regenerative medicine and highlights the need for ongoing biopharmaceutical research and innovation. Patent-specific References Title: "Preconditioning Human Tissue Allografts with Tolerogenic Dendritic Cells" Publication number: US 8,871,273 B2 Issue date: October 23, 2014 The detailed analysis provided indicates that Patent 8871273 grants exclusive rights to a novel method of preconditioning human tissue allografts with tolerogenic dendritic cells.

Drugs Protected by US Patent 8,871,273

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287-001	Jan 30, 2009	AB	RX	Yes	No			Y
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287-002	Jan 30, 2009	AB	RX	Yes	Yes			Y
Takeda Pharms Usa	DEXILANT SOLUTAB	dexlansoprazole	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL	208056-001	Jan 26, 2016		DISCN	Yes	No					Y

Foreign Priority and PCT Information for Patent: 8,871,273

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2005-051732	Feb 25, 2005

PCT Information
PCT Filed	February 24, 2006	PCT Application Number:	PCT/JP2006/303455
PCT Publication Date:	August 31, 2006	PCT Publication Number:	WO2006/090845

International Family Members for US Patent 8,871,273

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2599340
Canada	2784881
European Patent Office	1852100
European Patent Office	2275088
Spain	2550626
Spain	2675581